secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001193125-23-184752
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics: Dr. Adrian Hepner resigns as President/CMO, replaced by Dr. Fred Grossman
--------------------------------------------------------------------------------

- Dr. Fred Grossman appointed President and CMO effective July 17, 2023, succeeding Dr. Adrian Hepner who resigned.
- Base salary $450,000/year; annual bonus target 40% of base salary based on company-set objectives.
- Two option grants each for 74,069 shares (first on start date, second Jan 2024); 24,689 shares vest after 1 year, remainder over 24 months.
- Employment agreement initial term of 2 years, auto-renews annually unless either party gives 30-day notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523184752/0001193125-23-184752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312523184752/d530395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-184752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer